Recombinant Human CCL4/MIP-1 beta Protein

R&D Systems, part of Bio-Techne | Catalog # 271-BME

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Carrier Free
271-BME-010/CF
271-BME-050/CF
Catalog #
Availability
Size / Price
Qty
With Carrier
271-BME-010
271-BME-050
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Source

E. coli

Accession #

P13236.1

Conjugate

Unconjugated

Applications

Bioactivity

View all CCL4/MIP-1 beta Proteins and Enzymes »

Product Specifications

Source

E. coli-derived human CCL4/MIP-1 beta protein
Ala24-Asn92 (major); Pro30-Asn92 (Minor)

Purity

>97%, by SDS-PAGE under reducing conditions and visualized by silver stain.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Ala24 (Major); Pro30 (Minor)

Predicted Molecular Mass

7.8 kDa & 7.3 kDa

Activity

Measured by its ability to chemoattract BaF3 mouse pro-B cells transfected with human CCR5.
The ED50 for this effect is 1-6 ng/mL.

Reviewed Applications

Read 2 reviews rated 5 using 271-BME in the following applications:

Formulation, Preparation and Storage

Carrier Free
What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

Carrier: 271-BME
Formulation Lyophilized from a 0.2 μm filtered solution in Acetonitrile and TFA with BSA as a carrier protein.
Reconstitution Reconstitute at 100 μg/mL in sterile PBS containing at least 0.1% human or bovine serum albumin.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
Carrier Free: 271-BME/CF
Formulation Lyophilized from a 0.2 μm filtered solution in Acetonitrile and TFA.
Reconstitution Reconstitute at 100 μg/mL in sterile PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: CCL4/MIP-1 beta

CCL4, also known as macrophage inflammatory protein 1 beta (MIP-1 beta) is a 7.8 kDa beta chemokine that is secreted at sites of inflammation by activated leukocytes, lymphocytes, vascular endothelial cells, and pulmonary smooth muscle cells (1, 2). CCL4 attracts a variety of immune cells to sites of microbial infection as well as to other pathologic inflammation such as allergic asthma and ischemic myocardium (3 - 8). A CCL4 deficiency in mice promotes the development of autoantibodies, possibly as a result of compromised regulatory T cell recruitment (6). CCL4 is secreted from activated monocytes as a heterodimer with CCL3/MIP-1 alpha (9). The first two N-terminal amino acids can be cleaved from human CCL4 by CD26/DPPIV (10, 11). Both the full length and truncated forms exert biological activity through CCR5, and the truncated form additionally interacts with CCR1 and CCR2b (10). In humans, the ability of CCL4 to bind CCR5 inhibits the cellular entry of M-tropic HIV-1 which utilizes CCR5 as a coreceptor (2). Both forms of CCL4 block HIV-1 infection of T cells by inducing the downregulation of CCR5 (10). Mature human CCL4 shares 77% and 80% aa sequence identity with mouse and rat CCL4, respectively.

References

  1. Rot, A. and U.H. von Andrian (2004) Annu. Rev. Immunol. 22:891.
  2. Menten, P. et al. (2002) Cytokine Growth Factor Rev. 13:455.
  3. Sun, X. et al. (2006) Infec. Immun. 74:5943.
  4. Bisset, L.R. and Schmid-Grendelmeier, P. (2005) Curr. Opin. Pulm. Med. 11:35.
  5. Frangogiannis, N.G. (2004) Inflamm. Res. 53:585.
  6. Bystry, R.S. et al. (2001) Nat. Immunol. 2:1126.
  7. Oliveira, S.H.P. et al. (2002) J. Leukoc. Biol. 71:1019.
  8. Schall, T.J. et al. (1993) J. Exp. Med. 177:1821.
  9. Guan, E. et al. (2001) J. Biol. Chem. 276:12404.
  10. Guan, E. et al. (2002) J. Biol. Chem. 277:32348.
  11. Guan, E. et al. (2004) J. Cell. Biochem. 92:53.

Alternate Names

Exodus-3, MIP-1 beta, MIP1 beta

Entrez Gene IDs

6351 (Human); 20303 (Mouse); 116637 (Rat); 448786 (Canine); 102117861 (Cynomolgus Monkey)

Gene Symbol

CCL4

UniProt

P13236.1

Additional CCL4/MIP-1 beta Products

Product Documents for Recombinant Human CCL4/MIP-1 beta Protein

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Download SDS 271-BME (with carrier)
Download SDS 271-BME/CF (carrier free)

Product Specific Notices for Recombinant Human CCL4/MIP-1 beta Protein

For research use only

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.